Navigation Links
Controversial physical agents directive postponed
Date:10/29/2007

Brussels, 29 October 2007 - The implementation of the Physical Agents Directive 2004/40/EC would suppose irreversible and drastic repercussions for cancer diagnosis and treatment Europe wide. Last Fridays publicly announced postponement represents a thankful turnaround, putting the brakes on a feared future for Magnetic Resonance Imaging (MRI) in cancer.

Two-way dialogue prior to policy is paramount

The Physical Agents Directive was originally devised to limit occupational radiation exposure. What the Directive however failed to consider in its parameters were the different boundaries relating to such exposure. This oversight has greatly concerned professionals involved in cancer diagnosis and treatment.

The Directive would consequently breach even those operating within 1 metre of MRI scanners as shown by a study published by the Health and Safety Executive in June 2007 on operator exposure to electromagnetic fields from MRI (Stuart Crozier, Brisbane University, Australia). These findings have thankfully and subsequently been considered by the European Commission.

At the recent ECCO 14 meeting, the dangers behind implementing the Directive were tackled head on by Dag Rue Olsen (Norwegian Radiation Hospital, Norway), Chairman, Physics Committee, the European Society for Therapeutic Radiology and Oncology (ESTRO) during a specially organised news briefing.

Accentuating the problems with the Directive, Olsen emphasised that MRI is an essential tool in medical diagnostics and argued that there is no scientific evidence of long-term adverse health effects of exposure to static fluctuating magnetic fields that are commonly found during MR scanning. Concerning the recent announcement, he commented,

It is important to welcome this development as a first step in avoiding severe consequences for cancer patients. Importantly, there is a lesson to be learned from this particular turn of events. The Commission should widely consult and collaborate with all stakeholders in cancer treatment and care prior to setting future directives. It would be wise for the EC to involve organisations such as ECCO as partners in redefining the Directive based on sound science.

Protecting progress, professionals and patients

Deferring the Directive does not merit a whole hearted congratulatory note. ECCO responds with caution since the headline here supposes a first step postponement as opposed to ultimate reversal. If policy mindset surrounding the implementation endures, todays public announcement will sadly be buried with yesterdays news.

ECCO is highly committed to actively engaging with policymakers to help ensure that future legislation does not imply a similarly negative impact. By connecting major players in cancer research, treatment and care, ECCO is now better placed to engage with policymakers to promote the interests of cancer patients, the carers, and those without whose research there would be no advancement in cancer.

We must all accept and assume the responsibility of getting involved in 'cancer politics. Without such collective commitment, we can ourselves be equally accused of hindering progress, punishing our respective professions, and falling far short in following the ECCO philosophy that every cancer patient deserves the best.


'/>"/>

Contact: Amanda Wren
amanda.wren@ecco-org.eu
32-473-938-672
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Controversial deal on public access of the human genome map
3. Controversial Levis jean ad to be withdrawn
4. GMC Gives Controversial Fertility Doctor, A Clean Chit
5. Controversial Theory Says DNA Can Be Pushed To "Dark States"
6. Harvard Begins Controversial Human Stem Cell Cloning Project
7. Controversial Vaccine Raises Fury of the Church
8. The Controversial Stem Cell Transplant Surgery a Failure, Patient died
9. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
10. Ever-Controversial Mental Health Act To Be Decided Upon
11. Cancer Experts Received Threats for Opposing Controversial Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Sterling, VA (PRWEB) , ... April 29, 2016 ... ... Americans with student loans more flexibility in repaying their loans, more information about ... at a time when total outstanding student loan debt, including federal and private ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... Hills, CA (PRWEB) , ... April 29, 2016 , ... ... of devices and products for the head and neck/ear, nose and throat specialty, has ... Device , The KOTLER NASAL AIRWAY™ is a newly patented safety device ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  While ... notably complement the company,s valve repair and stent ... move also places Abbott more firmly into patient ... of the fastest growing device areas, with double-digit ... its recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
Breaking Medicine Technology: